Your browser is no longer supported. Please, upgrade your browser.
CTSO Cytosorbents Corporation monthly Stock Chart
CTSO [NASD]
Cytosorbents Corporation
Index- P/E- EPS (ttm)-0.32 Insider Own1.20% Shs Outstand41.59M Perf Week-5.43%
Market Cap353.63M Forward P/E- EPS next Y-0.15 Insider Trans-1.55% Shs Float39.55M Perf Month3.08%
Income-11.10M PEG- EPS next Q-0.04 Inst Own40.50% Short Float7.68% Perf Quarter1.39%
Sales36.50M P/S9.69 EPS this Y-6.60% Inst Trans53.24% Short Ratio10.47 Perf Half Y-18.99%
Book/sh1.93 P/B4.33 EPS next Y39.10% ROA-19.70% Target Price- Perf Year112.18%
Cash/sh2.08 P/C4.02 EPS next 5Y- ROE-34.40% 52W Range3.49 - 11.74 Perf YTD117.14%
Dividend- P/FCF- EPS past 5Y14.30% ROI-96.70% 52W High-28.10% Beta0.41
Dividend %- Quick Ratio5.50 Sales past 5Y43.30% Gross Margin70.90% 52W Low141.86% ATR0.40
Employees156 Current Ratio5.60 Sales Q/Q72.10% Oper. Margin-36.30% RSI (14)50.76 Volatility3.90% 5.38%
OptionableYes Debt/Eq0.19 EPS Q/Q90.50% Profit Margin-30.50% Rel Volume0.52 Prev Close8.36
ShortableYes LT Debt/Eq0.07 EarningsNov 04 AMC Payout- Avg Volume290.30K Price8.44
Recom1.70 SMA20-0.33% SMA501.62% SMA2000.88% Volume57,403 Change0.97%
Sep-17-20Initiated Jefferies Buy $15
Sep-01-20Initiated SVB Leerink Outperform $15
Aug-08-17Reiterated Maxim Group Buy $10 → $12
Oct-26-16Initiated Aegis Capital Buy
May-24-16Initiated Maxim Group Buy $8
Oct-29-15Upgrade WBB Securities Speculative Buy → Buy $13 → $13
May-12-15Reiterated MLV & Co Buy $28 → $21
Apr-01-15Reiterated MLV & Co Buy $28 → $30
Mar-05-15Initiated MLV & Co Buy $30
Feb-25-15Initiated WBB Securities Speculative Buy $13
Jan-27-15Reiterated H.C. Wainwright Buy $1 → $12
Nov-25-20 07:08AM  
Nov-23-20 07:00AM  
Nov-12-20 02:00AM  
Nov-10-20 05:25AM  
Nov-06-20 06:05AM  
Nov-04-20 08:31PM  
04:48PM  
04:15PM  
02:45PM  
Nov-03-20 10:08AM  
Oct-21-20 07:08AM  
Oct-14-20 07:00AM  
Oct-09-20 07:08AM  
Sep-21-20 07:08AM  
Sep-19-20 10:45AM  
Sep-11-20 08:00AM  
Sep-08-20 07:08AM  
Sep-01-20 04:50PM  
09:47AM  
Aug-24-20 07:00AM  
Aug-17-20 07:08AM  
Aug-06-20 09:05AM  
Aug-05-20 09:01AM  
Aug-04-20 05:18PM  
04:15PM  
Aug-03-20 12:47PM  
07:00AM  
Jul-31-20 07:08AM  
Jul-28-20 07:08AM  
06:00AM  
Jul-22-20 12:31PM  
07:22AM  
Jul-21-20 03:48PM  
07:15AM  
Jul-20-20 04:51PM  
04:26PM  
Jul-08-20 07:00AM  
Jun-29-20 07:08AM  
Jun-25-20 12:27PM  
Jun-24-20 07:30AM  
Jun-19-20 05:40AM  
Jun-09-20 07:08AM  
Jun-06-20 08:05AM  
May-27-20 12:00PM  
May-19-20 08:03AM  
May-12-20 07:08AM  
May-08-20 02:24PM  
May-06-20 03:01PM  
May-05-20 04:15PM  
May-04-20 07:08AM  
Apr-28-20 08:00AM  
Apr-27-20 07:08AM  
Apr-20-20 06:58AM  
Apr-15-20 07:00AM  
Apr-13-20 03:31PM  
11:44AM  
10:06AM  
07:43AM  
Apr-03-20 12:06PM  
Mar-31-20 07:08AM  
Mar-30-20 04:23PM  
Mar-25-20 07:19AM  
Mar-12-20 09:33AM  
Mar-05-20 04:15PM  
02:45PM  
Mar-02-20 07:00AM  
Feb-28-20 07:00AM  
Feb-19-20 07:00AM  
Feb-05-20 07:51AM  
Feb-02-20 08:25AM  
Jan-29-20 07:25AM  
06:38AM  
Jan-28-20 07:01AM  
Jan-22-20 06:30AM  
Jan-14-20 09:30AM  
Jan-10-20 04:11PM  
Jan-07-20 10:13AM  
Dec-20-19 05:02PM  
Dec-11-19 05:23AM  
Dec-02-19 07:45AM  
Nov-25-19 07:00AM  
Nov-19-19 07:00AM  
Nov-06-19 05:15PM  
Nov-05-19 04:15PM  
05:52AM  
Nov-04-19 07:05AM  
Nov-01-19 07:15AM  
Oct-30-19 07:30AM  
Oct-22-19 08:12AM  
Oct-15-19 08:00AM  
Oct-11-19 06:59AM  
Oct-10-19 07:00AM  
Oct-04-19 07:08AM  
Oct-02-19 08:24AM  
Sep-25-19 06:58AM  
Sep-21-19 08:44AM  
Sep-19-19 10:15AM  
Sep-16-19 07:00AM  
Sep-13-19 07:08AM  
Sep-09-19 07:00AM  
Cytosorbents Corporation, a critical care focused immunotherapy company, engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology. The company's flagship product is CytoSorb device, an extracorporeal cytokine filter designed for the adjunctive therapy in the treatment of sepsis; adjunctive therapy in other critical care applications; prevention and treatment of post-operative complications of cardiopulmonary bypass surgery; prevention and treatment of organ dysfunction in brain-dead organ donors to increase the number and quality of viable organs harvested from donors; and VetResQ device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals. The company also develops CytoSorb-XL device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients; K+ontrol for treatment of severe hyperkalemia with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it is involved in the development of BetaSorb device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; and DrugSorb, a development-stage extracorporeal hemoperfusion cartridge designed to remove toxic chemicals from the blood. The company was formerly known as MedaSorb Technologies Corporation and changed its name to CytoSorbents Corporation in May 2010. The company was founded in 1997 and is based in Monmouth Junction, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Kraus AlDirectorNov 10Option Exercise3.458,00027,600133,046Nov 12 05:31 PM
Kraus AlDirectorNov 10Sale8.008,00064,000125,046Nov 12 05:31 PM
Jones Edward RaymondDirectorAug 18Option Exercise3.354,00013,40078,800Aug 20 04:10 PM
BLOCH KATHLEEN P.Chief Financial OfficerJul 31Option Exercise5.6010,00056,000325,156Aug 04 04:31 PM
Capponi VincentPresident and COOMay 05Option Exercise9.2610,12393,739427,772May 07 06:01 PM
Chan Phillip P.Chief Executive OfficerMay 05Option Exercise9.3914,100132,399714,682May 07 06:00 PM
Capponi VincentChief Operating OfficerApr 27Option Exercise2.8810,00028,750427,649Apr 29 04:15 PM
Capponi VincentChief Operating OfficerApr 27Sale10.0010,000100,000417,649Apr 29 04:15 PM
Capponi VincentChief Operating OfficerMar 10Option Exercise3.4511,17738,561422,326Mar 12 09:39 PM
Capponi VincentChief Operating OfficerMar 10Sale6.004,67728,062417,649Mar 12 09:39 PM
BLOCH KATHLEEN P.Chief Financial OfficerDec 10Buy3.683,00011,030291,895Dec 10 01:30 PM
Chan Phillip P.President and CEODec 06Buy3.6016,50059,400657,688Dec 06 11:45 AM